Skip to main content

Table 1 Demographic and clinical characteristics of subjects

From: Comprehensive analysis of immunoglobulin and clinical variables identifies functional linkages and diagnostic indicators associated with Behcet’s disease patients receiving immunomodulatory treatment

   BD-N BD-C BD-I BD-C&I HC AAV TA
N 15 12 8 28 66 / /
Discovery set Age(y) 35.40 ± 10.16 27.25 ± 13.18 30.50 ± 6.80 31.04 ± 9.800 49.17 ± 13.51 / /
Sex(M/F) 10/5 7/5 4/4 20/8 31/35 / /
ICBD 5.73 ± 2.63 5.75 ± 1.36 5.00 ± 1.53 6.643 ± 1.890 / / /
Validation set N 27 5 16 / 30 18 18
Age(y) 37.81 ± 11.60 34.20 ± 12.40 36.94 ± 13.69 / 38.40 ± 11.40 51.89 ± 14.07 33.94 ± 10.46
Sex(M/F) 8/19 3/2 5/11 / 14/16 7/11 7/11
ICBD 5.19 ± 1.62 6.60 ± 0.89 5.50 ± 1.32 / / / /
  1. BD-N BD patients not receiving corticosteroid or immunosuppressant treatment, BD-C BD patients receiving only corticosteroid treatment, BD-I BD patients receiving only immunosuppressant treatment, BD-C&I BD patients receiving both corticosteroid and immunosuppressant treatment